Tocagen seeks $86M IPO to fund cancer gene therapy trial – FierceBiotech
FierceBiotech |
Tocagen seeks $86M IPO to fund cancer gene therapy trial
FierceBiotech Tocagen has filed to raise up to $86 million in an IPO to take its breakthrough-designated brain cancer gene therapy combination through the first part of a phase 2/3 trial. The San Diego, California-based biotech expects to deliver data from the phase … |
